The top 5 most-watched video interviews of 2021 on AJMC.com addressed myths about COVID-19 vaccination, eye health, and dermatologic conditions, as well as the use of sodium glucose co-transporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes, chronic kidney disease, and heart failure.
The most-viewed video interviews on AJMC.com for 2021 discussed efficacy findings of sodium glucose co-transporter 2 (SGLT2) inhibitors for the treatment of chronic conditions, and myths about COVID-19 vaccination, and other pandemic about eye health and skin manifestations.
Here are the 5 most-viewed video interviews of 2021:
5. Dr Deepak Bhatt Discusses SCORED, SOLOIST Trial Results
Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, discussed positive findings of the SCORED and SOLOIST trials presented at the American Diabetes Association's (ADA) 81st Scientific Sessions. Both trials demonstrated the safety and efficacy of sotagliflozin, a SGLT2 inhibitor, in the treatment of chronic kidney disease, type 2 diabetes, and heart failure.
4. Dr Rajesh Rajpal on Eye Health Implications of Visual Needs in Younger Populations
In an interview, Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson (J&J) Vision, spoke about the substantial increase of visual needs in recent years and how eye conditions such as cataract have become more consequential at an earlier age. He also mentioned the process of cataract surgery and the different options available for patients in selecting intraocular lenses.
3. Dr William "Andy" Nish Debunks Common Reasons for Not Getting COVID-19 Vaccine
Discussing misconceptions about COVID-19 vaccines, William "Andy" Nish, MD, a medical director and provider with a specialty in allergy and immunology at Northeast Georgia Physicians Group in Gainesville, Georgia, emphasized the importance of getting vaccinated as soon as possible to protect one’s self, family, and community against the risk of infection. He noted that the risk of getting COVID-19 is much higher and much worse than the risks of getting the vaccine even for younger populations who would be considered at low risk of complications.
2. Dr Rajesh Rajpal Reviews Latest Innovations in Cataract Surgery
In another interview, Rajpal spoke further on the latest surgical options available to patients undergoing cataract surgery. He noted that intraocular lenses have now advanced to the point where there are various options that can help patients reduce their need for glasses after cataract surgery. At J&J, Rajpal said their use of the TECNIS family of intraocular lenses provides a wide range of lenses that can fix distance vision specifically or the continuous range of vision.
1. Dr Christine Ko: “COVID Toes” Not Active Skin Infection
Christine Ko, MD, professor of dermatology and pathology at Yale University, addressed skin-related toe manifestations of COVID-19 called perniosis. Dr Ko described perniosis as a discoloration of the skin that mostly affects the toes and can also manifest in other parts of the foot. However, she said that COVID-19 is not an active infection of the skin despite these reported instances.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More